<DOC>
	<DOCNO>NCT00561015</DOCNO>
	<brief_summary>The purpose study assess effect telaprevir early hepatitis ( inflammation liver ) C virus ( HCV ) viral kinetics treatment-naive participant chronically ( last long time ) infect genotype 2 3 HCV .</brief_summary>
	<brief_title>A Phase 2a Study Evaluate Viral Kinetics Safety Telaprevir Participants With Genotype 2 3 Hepatitis C Infection</brief_title>
	<detailed_description>This Phase 2a multicenter ( one hospital medical school team work medical research study ) , partially blind , randomize ( study drug assign chance ) stratify ( arrange group analysis result e.g. , stratify age , sex , etc . ) genotype , multiple dose study . The trial consist Screening period ( 6 week ) , Treatment period ( 24 26 week ) Follow-up period ( 24 week ) . The Treatment period include 2 week investigational treatment phase 24 week standard treatment phase . All eligible participant never treat HCV enrol trial receive investigational treatment regimen randomly assign 2 week . After standard treatment phase participant receive standard treatment care consist pegylated interferon ( Peg-IFN ) -alfa-2a 180 microgram weekly ribavirin ( RBV ) 400 milligram twice per day . Efficacy primarily evaluate HCV viral load quantification . Participant 's safety monitor throughout study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Participants chronically infect genotype 2 3 hepatitis C virus ( HCV ) amount virus blood great 10,000 international unit per milliliter ( IU/ml ) Participants never treat hepatitis C virus infection Participants without significant lab abnormality Participants agree use two effective method contraception Participant judge good health Participants contraindication start antiHCV therapy Participants history evidence liver cirrhosis ( serious liver disorder connective tissue replaces normal liver tissue , liver failure often occur ) decompensated liver disease hepatocellular carcinoma ( type cancer ) Participant infect human immunodeficiency virus ( lifethreatening infection get infect person 's blood sex infect person ) hepatitis B virus Females pregnant ( carry unborn baby ) , plan pregnant breastfeeding Participants hypersensitivity tartrazine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Genotype 3</keyword>
	<keyword>Telaprevir</keyword>
</DOC>